Search research articles
Contact Us
Filters
Showing results (1-10 of 8) with videos related to
Page
of 1
Sort By:
The Annals of Pharmacotherapy
|
August 4, 2001
Cost-effectiveness results from the US Carvedilol Heart Failure Trials Program
M Vera-Llonch, J Menzin, R E Richner, et al.
Current Medical Research and Opinion
|
September 19, 2007
Cost-effectiveness analysis of pregabalin versus gabapentin in the management of neuropathic pain due to diabetic polyneuropathy or post-herpetic neuralgia
M J Rodríguez, S Díaz, M Vera-Llonch, et al.
Journal of Viral Hepatitis
|
February 18, 2014
Work productivity among treatment-naïve patients with genotype 1 chronic hepatitis C infection receiving telaprevir combination treatment
J Aggarwal, M Vera-Llonch, M Donepudi, et al.
The American Journal of Cardiology
|
April 6, 1999
Cost effectiveness of carvedilol for heart failure
T E Delea, M Vera-Llonch, R E Richner, et al.
Alimentary Pharmacology & Therapeutics
|
June 4, 2013
Health-related quality of life in genotype 1 treatment-naïve chronic hepatitis C patients receiving telaprevir combination treatment in the ADVANCE study
M Vera-Llonch, M Martin, J Aggarwal, et al.
Revista De Neurologia
|
October 20, 2007
[Analysis of the cost-effectiveness of treatment for refractory partial epilepsy: a simulation model for pregabalin and levetiracetam]
S Díaz, A Argumosa, J F Horga de la Parte, et al.
Rheumatology (Oxford, England)
|
March 22, 2008
Cost-effectiveness of abatacept in patients with moderately to severely active rheumatoid arthritis and inadequate response to methotrexate
M Vera-Llonch, E Massarotti, F Wolfe, et al.
Journal of the American College of Cardiology
|
May 10, 2001
Influence of carvedilol on hospitalizations in heart failure: incidence, resource utilization and costs. U.S. Carvedilol Heart Failure Study Group
M B Fowler, M Vera-Llonch, G Oster, et al.
Page
of 1
Search research articles
Search
Showing results (1-10 of 8) with videos related to
Sort By:
Page
of 1
The Annals of Pharmacotherapy
|
August 4, 2001
Cost-effectiveness results from the US Carvedilol Heart Failure Trials Program
M Vera-Llonch, J Menzin, R E Richner, et al.
Current Medical Research and Opinion
|
September 19, 2007
Cost-effectiveness analysis of pregabalin versus gabapentin in the management of neuropathic pain due to diabetic polyneuropathy or post-herpetic neuralgia
M J Rodríguez, S Díaz, M Vera-Llonch, et al.
Journal of Viral Hepatitis
|
February 18, 2014
Work productivity among treatment-naïve patients with genotype 1 chronic hepatitis C infection receiving telaprevir combination treatment
J Aggarwal, M Vera-Llonch, M Donepudi, et al.
The American Journal of Cardiology
|
April 6, 1999
Cost effectiveness of carvedilol for heart failure
T E Delea, M Vera-Llonch, R E Richner, et al.
Alimentary Pharmacology & Therapeutics
|
June 4, 2013
Health-related quality of life in genotype 1 treatment-naïve chronic hepatitis C patients receiving telaprevir combination treatment in the ADVANCE study
M Vera-Llonch, M Martin, J Aggarwal, et al.
Revista De Neurologia
|
October 20, 2007
[Analysis of the cost-effectiveness of treatment for refractory partial epilepsy: a simulation model for pregabalin and levetiracetam]
S Díaz, A Argumosa, J F Horga de la Parte, et al.
Rheumatology (Oxford, England)
|
March 22, 2008
Cost-effectiveness of abatacept in patients with moderately to severely active rheumatoid arthritis and inadequate response to methotrexate
M Vera-Llonch, E Massarotti, F Wolfe, et al.
Journal of the American College of Cardiology
|
May 10, 2001
Influence of carvedilol on hospitalizations in heart failure: incidence, resource utilization and costs. U.S. Carvedilol Heart Failure Study Group
M B Fowler, M Vera-Llonch, G Oster, et al.
Page
of 1